Australia’s New Patent Box: Unboxed
Following a cacophony of dire warnings and lobbying over the past decade from the Australian biotechnology and medical sectors, and the sudden sharp focus of middle Australia on the...
Following a cacophony of dire warnings and lobbying over the past decade from the Australian biotechnology and medical sectors,...
Read More
TGA proposes far-reaching changes to support the repurposing of prescription medicines
The Therapeutic Goods Administration (TGA) has commenced a timely public consultation into the repurposing of prescription medicines, which seeks to better understand the incentives and potential hurdles influencing sponsors’...
The Therapeutic Goods Administration (TGA) has commenced a timely public consultation into the repurposing of prescription medicines, which seeks...
Read More
Pfizer preliminary discovery attempt on ERELZI fails
In this Federal Court case, Pfizer’s attempt to obtain documentation from Sandoz regarding its ERELZI etanercept product failed, Justice Burley finding that undertakings provided by Sandoz to give notice...
In this Federal Court case, Pfizer’s attempt to obtain documentation from Sandoz regarding its ERELZI etanercept product failed, Justice...
Read More
Biological deposits under the Budapest Treaty
In order to obtain patent protection in Australia, an invention must be novel, involve an inventive step and have industrial applicability. There is also a disclosure and enablement requirement...
In order to obtain patent protection in Australia, an invention must be novel, involve an inventive step and have...
Read More
Pfizer suffers setback in ENBREL battle
Pfizer suffered a setback last week in its Australian battle to protect ENBREL (etanercept), when its preliminary discovery application against Sandoz was dismissed by Justice Burley in the Federal...
Pfizer suffered a setback last week in its Australian battle to protect ENBREL (etanercept), when its preliminary discovery application...
Read More
Australian Patent Office considers the plausibility of Swiss-style claims
Gliknik, Inc. v CSL Behring Lengnau AG  APO 46 (“Gliknik”) concerned a patent application for engineered proteins intended for use as replacements for intravenous immunoglobulin.  The application included claims...
Gliknik, Inc. v CSL Behring Lengnau AG  APO 46 (“Gliknik”) concerned a patent application for engineered proteins intended for...
Read More
Pharmaceutical patent term extensions: broader is not always better
Ono Pharmaceutical Co., Ltd. et al  APO 43 (16 September 2020) Background Australia’s Patents Act provides a patent term extension (PTE) to account for the delays that can occur when obtaining...
Ono Pharmaceutical Co., Ltd. et al  APO 43 (16 September 2020) Background Australia’s Patents Act provides a patent term extension (PTE)...
Read More